Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Smith-and-Nephew SNATS stock

Learn how to easily invest in Smith-and-Nephew SNATS stock.

Smith & Nephew SNATS Inc is a medical devices business based in the US. Smith-and-Nephew SNATS shares (SNN) are listed on the NYSE and all prices are listed in US Dollars. Smith-and-Nephew SNATS employs 18,000 staff and has a trailing 12-month revenue of around $5.2 billion.

How to buy shares in Smith-and-Nephew SNATS

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SNN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Smith-and-Nephew SNATS stock price (NYSE: SNN)

Use our graph to track the performance of SNN stocks over time.

Smith-and-Nephew SNATS shares at a glance

Information last updated 2022-09-26.
Latest market close$21.95
52-week range$21.80 - $36.75
50-day moving average $25.64
200-day moving average $30.51
Wall St. target price$35.80
PE ratio 19.3319
Dividend yield $0.375 (3.33%)
Earnings per share (TTM) $1.13

Buy Smith-and-Nephew SNATS shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 8 of 8
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Smith-and-Nephew SNATS stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Smith-and-Nephew SNATS price performance over time

Historical closes compared with the close of $21.95 from 2022-09-27

1 week (2022-09-21) -5.02%
1 month (2022-08-26) -7.70%
3 months (2022-06-28) -21.55%
6 months (2022-03-28) -32.65%
1 year (2021-09-28) -38.91%
2 years (2020-09-28) -42.48%
3 years (2019-09-27) 47.96
5 years (2017-09-28) 36

Is Smith-and-Nephew SNATS stock undervalued or overvalued?

Valuing Smith-and-Nephew SNATS stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Smith-and-Nephew SNATS's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Smith-and-Nephew SNATS's P/E ratio

Smith-and-Nephew SNATS's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Smith-and-Nephew SNATS shares trade at around 19x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Smith-and-Nephew SNATS's PEG ratio

Smith-and-Nephew SNATS's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1769. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Smith-and-Nephew SNATS's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Smith-and-Nephew SNATS's EBITDA

Smith-and-Nephew SNATS's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.2 billion.

The EBITDA is a measure of a Smith-and-Nephew SNATS's overall financial performance and is widely used to measure a its profitability.

Smith-and-Nephew SNATS financials

Revenue TTM $5.2 billion
Operating margin TTM 13.72%
Gross profit TTM $3.7 billion
Return on assets TTM 4.25%
Return on equity TTM 9.25%
Profit margin 9.52%
Book value $12.31
Market capitalisation $9.6 billion

TTM: trailing 12 months

Smith-and-Nephew SNATS share dividends


Dividend payout ratio: 66.25% of net profits

Recently Smith-and-Nephew SNATS has paid out, on average, around 66.25% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.33% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Smith-and-Nephew SNATS shareholders could enjoy a 3.33% return on their shares, in the form of dividend payments. In Smith-and-Nephew SNATS's case, that would currently equate to about $0.375 per share.

Smith-and-Nephew SNATS's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Smith-and-Nephew SNATS's most recent dividend payout was on 25 October 2022. The latest dividend was paid out to all shareholders who bought their shares by 30 March 2022 (the "ex-dividend date").

Have Smith-and-Nephew SNATS's shares ever split?

Smith-and-Nephew SNATS's shares were split on a 2499:1000 basis on 14 October 2014. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 2499 shares. This wouldn't directly have changed the overall worth of your Smith-and-Nephew SNATS shares – just the quantity. However, indirectly, the new 60% lower share price could have impacted the market appetite for Smith-and-Nephew SNATS shares which in turn could have impacted Smith-and-Nephew SNATS's share price.

Smith-and-Nephew SNATS share price volatility

Over the last 12 months, Smith-and-Nephew SNATS's shares have ranged in value from as little as $21.8 up to $36.7483. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Smith-and-Nephew SNATS's is 0.4021. This would suggest that Smith-and-Nephew SNATS's shares are less volatile than average (for this exchange).

Smith-and-Nephew SNATS overview

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Frequently asked questions

What percentage of Smith-and-Nephew SNATS is owned by insiders or institutions?
Currently 0.045% of Smith-and-Nephew SNATS shares are held by insiders and 8.957% by institutions.
How many people work for Smith-and-Nephew SNATS?
Latest data suggests 18,000 work at Smith-and-Nephew SNATS.
When does the fiscal year end for Smith-and-Nephew SNATS?
Smith-and-Nephew SNATS's fiscal year ends in December.
Where is Smith-and-Nephew SNATS based?
Smith-and-Nephew SNATS's address is: Building 5, Watford, United Kingdom, WD18 8YE
What is Smith-and-Nephew SNATS's ISIN number?
Smith-and-Nephew SNATS's international securities identification number is: US83175M2052
What is Smith-and-Nephew SNATS's CUSIP number?
Smith-and-Nephew SNATS's Committee on Uniform Securities Identification Procedures number is: 043136100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site